Y-mabs presents neuroblastoma research on naxitamab and sada prit technology platform at aacr special conference on advances in pediatric cancer research

New york, sept. 06, 2024 (globe newswire) -- y-mabs therapeutics, inc. (the “company” or “y-mabs”) (nasdaq: ymab), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel radioimmunotherapy and antibody-based therapeutic products for the treatment of cancer, today announced new clinical and preclinical data from studies evaluating naxitamab and gd2-sada, respectively, in neuroblastoma. the results are summarized in poster presentations scheduled to be presented september 6 – 7, 2024, at the american academy of cancer research (“aacr”) special conference in the advances in pediatric cancer research in toronto, canada.
YMAB Ratings Summary
YMAB Quant Ranking